Wed. Oct 5th, 2022
Vaccine approval: The USFDA has set a high bar on transparency. Here’s what India can learn The Pfizer-BionNtech vaccine panel’s entire review meeting, which ran into some eight hours, was telecast live and is available on YouTube. In contrast, the recent meeting that reviewed Serum Institute of India’s emergency-use application for the ‘Covishield’ vaccine seems opaque. The DCGI statement on the meeting does not explain why domain expert Dr Sushant Meshram did not participate in the discussion. It did not even detail who took part in the meetings, who was present from the regulator’s side, and what views were expressed. An expert says there is no law prohibiting the government or regulator DCGI from sharing more information